Head-to-Head: which drug works best for stubborn Crohn's?
NCT ID NCT07149467
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial will compare two drugs—ustekinumab (a shot) and upadacitinib (a pill)—in 454 adults with Crohn's disease that didn't get better with standard anti-TNF therapy. The goal is to see which drug leads to more people feeling better by week 16. Both drugs are already approved for Crohn's, but they've never been directly compared in this type of patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ustekinumab and upadacitinib
- What this could lead to
- If this trial succeeds, it could show which of these two newer drugs works better for people with hard-to-treat Crohn's disease, helping doctors choose the best treatment.
- What could go wrong
- This is a head-to-head comparison, not a placebo-controlled trial, so it won't prove either drug works—only which one might be better. Results may not apply to all Crohn's patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE AGGRAVATED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.